CAR-T Cells Targeting uPAR Eliminate Senescent Cells and Restore Metabolic Function in Aged Mice

The study adapted cancer CAR-T methods by attaching a chimeric antigen receptor to murine T cells that recognizes urokinase plasminogen activator receptor, a surface marker upregulated on senescent cells. Single low-dose infusions produced durable cell engraftment, reduced tissue inflammation, and improved regenerative capacity in gut epithelium, an outcome linked to better systemic glucose handling. Unlike senolytic small molecules that require chronic administration, the modified T cells persisted and continued surveillance, addressing the core immune-aging defect rather than only its downstream cellular debris.

Context from oncology shows CAR-T persistence can last years after infusion, yet standard cancer doses trigger cytokine storms; here the far lower senescent-cell burden permitted safer dosing. The intervention also highlights gut-liver axis effects that mainstream senolytic trials have under-examined, suggesting immune clearance may recalibrate microbiota-immune crosstalk that accelerates frailty.

Next steps include dose-escalation studies in non-human primates to confirm blood-brain-barrier exclusion and long-term oncogenic risk, followed by IND-enabling toxicology packages. Regulatory precedent from CD19 CAR-T approvals provides a template, yet aging indications will demand new endpoints focused on composite frailty indices rather than tumor burden.